Estimated glomerular filtration rate (eGFR): This blood test measures how well your kidneys are filtering blood based on how muchcreatinine(a waste product created by the normal breakdown of muscles) is found in your blood. Urine albumin-creatinine ratio (uACR): This urine test measures how well...
YERVOY® (ipilimumab) as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread to other parts of your body (metastatic) and your tumors are positive for PD-L1, but do not have an abnormal EGFR or ...
Overall survival has steadily moved from being the primary to a secondary endpoint. However, it is still of interest with papers presenting overall survival results with the caveat of subsequent treatments, but little or no investigation into their effect. This review shows that there is a methodol...
The tests detect traces of disease in a patient’s blood. Here’s how they’re used—and why scientists hope they’re the future of cancer screening.
the biochemistry of EGFR-EGFR interactions is still being worked out by multiple labs after more than 30 years of intensive study. For instance, it is not proven how extracellular dimerization results in kinase-domain dimerization, or how the C-terminal tail (which is intrinsically denatured)...
the results can be influenced by using an effective half-life derived from a patient population, as there is inter-patient variability, especially in lesion kinetics [78]. This method assumes that the patient’s pharmacokinetics are similar to those of the cohort. It may be relevant to establis...
Moreover, Nivolumab plus ipili- mumab in first-line NSCLC patients had longer overall survival (OS) compared to chemotherapy and was not associated with PD-L1 expression levels [5]. In addition, in EGFR/ALK-altered NSCLC, there was no difference in survival between patients with tumor PD-L1...
In particular, we do thousands of tests and know that our interventions do not carry much risk for me. But all of us have different bodies. For example I have kidney function with eGFR of >160 (in the top 1% of 30-year-olds), whereas you might not. This means your risks may be ...
The T790M missense mutation occurs within the EGFR kinase domain and prevents binding of Gefitinib to this region while preserving catalytic activity [44]. In their study, the sampling interval used varied from 30 to 100 days, which corresponds to 2–7 bi-weekly cycles of chemotherapy [20]. ...
Learn how KEYTRUDA® (pembrolizumab) works with your immune system to help fight cancer cells. Watch two videos about immunotherapy and how it works in the body.